PF-4942847 - CAS 1046859-34-0

PF-4942847, a novel oral Hsp90 inhibitor, has emerged as a candidate compound for clinical development in TNBC by synergistically targeting multiple signaling pathways. Furthermore, the degradation of AKT in PBLs may serve as a biomarker in clinical development.

1046825

C20H18Cl2F3N7O2

516.3

O=C(NCC(F)(F)F)N1CC=2N=C(N=C(C=3C(Cl)=CC(Cl)=CC3OCCN4N=CC=C4)C2C1)N

-20°C

Ice Packs

Small Compound